FDA Clears GSK’s Twice-Yearly Asthma Drug, Signaling Shift in Biologic Care
PHILADELPHIA, PA — GSK plc (LSE/NYSE: GSK) said the U.S. Food and Drug Administration has approved Exdensur, a twice-yearly biologic treatment for patients with severe asthma characterized by an eosinophilic …
FDA Clears GSK’s Twice-Yearly Asthma Drug, Signaling Shift in Biologic Care Read More